{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-065961","form_type":"8-K","ticker":"BTMD","cik":"0001819253","company_name":"biote Corp.","filed_at":"2024-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.675565+00:00","generated_at":"2026-06-04T23:15:04.735393+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biote Q4 revenue $45.7M (+2.7% YoY), net income $12.1M; FY adj. EBITDA $55.3M (+10.2%)","bullets":["Q4 procedure revenue $34.9M (+6.6%); gross margin 69.4% (up >400 bps); diluted EPS $0.18.","Full-year revenue $185.4M (+12.4%); net loss $2.8M; adj. diluted EPS $0.13.","Practitioner network grew to 7,100 from 6,400; launched BioteRx hormone/wellness line.","Agreed to repurchase 18.4M founders' shares plus separate $20M buyback program.","Reaffirmed 2024 guidance with expectation of accelerated growth in H2."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-065961","json":"https://secwatch.observer/filing/0001193125-24-065961.json","markdown":"https://secwatch.observer/filing/0001193125-24-065961.md","text":"https://secwatch.observer/filing/0001193125-24-065961.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819253/000119312524065961/0001193125-24-065961-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819253/000119312524065961/d759704d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:15:04.735393+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3aeda499bd6f56333d7e0b905b176a83ed22f195","claim":"biote Corp. reported the fourth quarter ended December 31, 2023 results: revenue $45.7 million, net income $12.1 million, EPS $0.18. Guidance reaffirmed.","evidence_excerpt":"quarter and full year ended December 31, 2023. Fourth Quarter 2023 Financial Highlights (All financial result comparisons made are against the prior-year period) • Revenue of $45.7 million, a 2.7% increase and in line with pre-released financial guidance • Procedure revenue of $34.9 million, up 6.6% • Gross profit margin of 69.4%, a more than 400-basis point","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819253/000119312524065961/0001193125-24-065961-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended December 31, 2023"},{"label":"Revenue","value":"$45.7 million"},{"label":"Net income","value":"$12.1 million"},{"label":"EPS","value":"$0.18"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"a7109e4ee348370a03442a5b7bc5fdf2616b3da4","claim":"biote Corp. reported the full year ended December 31, 2023 results: revenue $185.4 million, net income $(2.8) million, EPS $0.13 per diluted share. Guidance reaffirmed.","evidence_excerpt":"financial guidance • Adjusted EBITDA margin 1 of 29.7% Full Year 2023 Financial Highlights (All financial result comparisons made are against the prior year) • Revenue of $185.4 million, a 12.4% increase • Procedure revenue of $141.0 million, up 9.3% • Gross profit margin of 68.8%, an approximately 190-basis point increase • Net loss of $(2.8) million,","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1819253/000119312524065961/0001193125-24-065961-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2023"},{"label":"Revenue","value":"$185.4 million"},{"label":"Net income","value":"$(2.8) million"},{"label":"EPS","value":"$0.13 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}